Teacher Retirement System of Texas Acquires 396 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Teacher Retirement System of Texas boosted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 8.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,857 shares of the company’s stock after purchasing an additional 396 shares during the quarter. Teacher Retirement System of Texas’ holdings in Disc Medicine were worth $308,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in shares of Disc Medicine during the 3rd quarter valued at about $146,000. Intech Investment Management LLC purchased a new stake in Disc Medicine during the third quarter valued at approximately $228,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after purchasing an additional 593 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Disc Medicine in the 3rd quarter worth approximately $445,000. Finally, HighVista Strategies LLC bought a new position in shares of Disc Medicine during the 3rd quarter valued at approximately $470,000. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a report on Friday, March 7th. Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. Stifel Nicolaus boosted their target price on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine has a consensus rating of “Buy” and an average price target of $93.80.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $47.15 on Wednesday. The stock has a market cap of $1.63 billion, a PE ratio of -11.85 and a beta of 0.73. The firm has a fifty day moving average price of $54.20 and a 200 day moving average price of $56.21. Disc Medicine, Inc. has a 1 year low of $25.64 and a 1 year high of $68.73.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. As a group, equities analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Activity at Disc Medicine

In related news, insider Rahul Khara sold 7,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total transaction of $470,625.00. Following the sale, the insider now directly owns 14,035 shares of the company’s stock, valued at approximately $880,696.25. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John D. Quisel sold 5,574 shares of Disc Medicine stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $304,228.92. Following the completion of the transaction, the chief executive officer now directly owns 154,828 shares of the company’s stock, valued at $8,450,512.24. The trade was a 3.48 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 369,190 shares of company stock worth $20,118,719. 4.24% of the stock is owned by corporate insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.